Was gibt es Neues in der Therapie der Fibromyalgie?

Späth, M.

doi:10.1007/s00482-003-0256-4

Cited by 8 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serotonin modulates the release of substance P, GABA, dopamine, cholecystokinin, acetylcholine, NKA, and CGRP [180,181]. Several receptors have been identified, and the 5-HT3 subtype appears to mediate inflammation [182].…”

Section: Novel Approaches To Downregulating Neurogenic Inflammationmentioning

confidence: 97%

Substance P in Rheumatic Diseases

Seidel

Tsalik²,

Vetter³

et al. 2007

CRR

View full text Add to dashboard Cite

Inflammation in many autoimmune syndromes is modulated by the nervous system. This paper reviews important principles of neurogenic inflammation and findings of substance P overexpression in rheumatic diseases. Substance P is a key molecule in activating inflammation after antidromal axoplasmic transport and secretion at the nociceptor. We summarize the results from studies with rheumatoid arthritis, osteoarthritis, psoriatic arthritis, systemic lupus erythematodes, systemic sclerosis, vasculitides, Sjögren syndrome, vasculitides, reflex sympathetic dystrophy, gouty arthritis, fibromyalgia syndrome, chronic fatigue syndrome and degenerative vertebral spine disorders. Although substance P is associated with many of these diseases, selective receptor blockers have not been effective in therapy. In contrast, the nonselective antagonist capsaicin is beneficial in some conditions. We also discuss a novel therapeutic principle with selective serotonin antagonists that may induce a powerful downregulation of neurogenic inflammation.

show abstract

Section: Novel Approaches To Downregulating Neurogenic Inflammationmentioning

confidence: 97%

Substance P in Rheumatic Diseases

Seidel

Tsalik²,

Vetter³

et al. 2007

CRR

View full text Add to dashboard Cite

show abstract

“…Several NK1 antagonists have been tested in clinical trials for chronic pain. However, these compounds have not been successful in demonstrating analgesia [25]. In contrast, a CGRPR antagonist, Telcagepant (MK-0974), has shown efficacy against migraine [26].…”

Section: Spinal Cord Mechanisms Of Chronic Pain and Clinical Implicatmentioning

confidence: 99%

Spinal Cord Mechanisms of Chronic Pain and Clinical Implications

Cheng

2010

Curr Pain Headache Rep

View full text Add to dashboard Cite

Chronic pain is a prevalent and challenging problem for most medical practitioners. Due to complex pathological mechanisms involved in chronic pain, optimal treatment is still under development. The spinal cord is an important gateway for peripheral pain signals transmitted to the brain. In chronic pain states, painful stimuli trigger afferent fibers in the dorsal horn to release neuropeptides and neurotransmitters. These events induce multiple inflammatory and neuropathic processes in the spinal cord dorsal horn and trigger modification and plasticity of local neural circuits. As a result, ongoing noxious signals to the brain are amplified and prolonged, a phenomenon known as central sensitization. In this review, the molecular events associated with central sensitization as well as their clinical implications are discussed.

show abstract

“…Das analgetische Potenzial von neueren pharmakologischen Wirkprinzipien wie NMDA-Glutamatrezeptorantagonisten (Henriksson u. Sorensen 2002), Neurokinin 1-Rezeptorantagonisten (Russell 2002) und 5-HT3-Rezeptorantagonisten (Späth 2003;Faerber et al 2007) wird derzeit klinisch überprüft. Seit kurzem wird der 5-HT3-Rezeptorantagonist Tropisetron in der intravenösen Kurzzeitbehandlung bei Fibromyalgieschmerzen eingesetzt.…”

Section: Fibromyalgiesyndromunclassified

Psychopharmakotherapie somatoformer Störungen und funktioneller somatischer Syndrome

Kapfhammer

2007

Psychiatrie

View full text Add to dashboard Cite

Patients presenting with bodily symptoms and complaints that are not explained by organic pathology or well known pathophysiological mechanisms form a major challenge to any health delivery system. From a perspective of psychiatric classification these medically unexplained somatic symptoms may be diagnosed as depressive and anxiety disorders on the one hand, as somatoform disorders on the other. Among medical specialties a separate diagnostic approach is taken to conceptualize functional somatic syndromes. From a therapeutic perspective psychotherapeutic strategies play a decisive role. There are also important issues that form a rationale for psychopharmacological interventions. The empirically significant overlap of somatoform syndromes and anxiety and depressive disorders, the conceptualization as affective spectrum disorders, the prominent role of pain symptoms, major neurobiological factors of underlying stress mechanisms, and high rates of psychiatric comorbidity in the often chronic courses of illness also stress the importance of psychopharmacotherapy. A survey will be presented on empirical studies of psychopharmacotherapy in somatoform disorders and some specific somatisation syndromes as fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and premenstrual syndrome. Findings of the antidepressant treatment of somatic symptoms in major depression will be summarised.

show abstract

Was gibt es Neues in der Therapie der Fibromyalgie?

Cited by 8 publications

References 15 publications

Substance P in Rheumatic Diseases

Substance P in Rheumatic Diseases

Spinal Cord Mechanisms of Chronic Pain and Clinical Implications

Psychopharmakotherapie somatoformer Störungen und funktioneller somatischer Syndrome

Contact Info

Product

Resources

About